Fannie Mae, Freddie Mac shares tumble after conservatorship comments
On Tuesday, Stifel analysts reaffirmed a Buy rating for Rapport Therapeutics stock (NASDAQ:RAPP), maintaining a price target of $35.00. Currently trading at $9.40, the stock has significant upside potential, with analyst targets ranging from $28 to $42. This decision follows an Analyst Event where favorable updates were shared regarding the RAP-219 phase 2a study in FOS.
The study focuses on "long episodes," an EEG biomarker linked to clinical seizures. Rapport Therapeutics provided insights into the patient population enrolled so far, highlighting a concordance rate of over 90% between long episodes and EEG seizures. This high concordance supports the relevance of the long episode biomarker.
Additionally, the frequency of diary-recorded seizures was noted to be approximately 10 per month. This frequency positions the study to potentially reveal a clinical effect, which is seen as a significant point for investors still questioning the long episode biomarker’s impact.
Stifel analysts believe that RAP-219 has a strong potential to become an effective antiepileptic drug, owing to its selectivity and cleaner tolerability profile. With the next earnings report due on August 7, investors following this development should note that InvestingPro offers 8 additional key insights about RAPP’s financial health and market position.
In other recent news, Rapport Therapeutics has been active with several noteworthy developments. The company is currently in a Phase 2a proof-of-concept trial for its lead candidate, RAP-219, aimed at treating focal epilepsy. Results for this trial are anticipated in the third quarter of 2025, with the company having successfully completed enrollment. Citizens JMP has maintained a Market Outperform rating for Rapport Therapeutics, setting a price target of $28, reflecting optimism about the potential of RAP-219. Analysts from the firm project that RAP-219 could achieve significant market penetration, potentially generating net U.S. sales of $1.1 billion by 2034.
In addition, Rapport Therapeutics has appointed Dr. Jeffrey Sevigny as its new chief medical officer. Dr. Sevigny brings extensive experience in drug development, having previously held leadership roles at Prevail Therapeutics (NASDAQ:PRVL) and Eli Lilly (NYSE:LLY). His focus will be on advancing the clinical strategy for the company’s pipeline, particularly the RAP-219 program. This appointment is expected to strengthen Rapport’s efforts in developing precision therapeutics for central nervous system disorders. The company has cautioned that its forward-looking statements are subject to risks, including clinical trial progress and regulatory approvals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.